Company news
Atossa Therapeutics, Inc. news in 2020
Atossa Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Atossa Therapeutics Announces Pricing of $14.0 Million Registered Direct Offering Priced At-The-Market
December 16, 2020
Atossa Therapeutics Announces Pricing of $20.0 Million Underwritten Public Offering
December 7, 2020
Atossa Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
November 12, 2020
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study Showing Safety and Tolerability of AT-301 Nasal Spray Being Developed for COVID-19
November 9, 2020
Atossa Therapeutics Completes Enrollment of Phase 1 Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
October 18, 2020
Atossa Therapeutics Receives Second Positive Interim Safety Assessment in Clinical Study of AT-301 Nasal Spray Being Developed for the Coronavirus Causing COVID
September 16, 2020
Atossa Therapeutics Announces Positive Interim Safety Assessment of First Group of Participants in Clinical Study of AT-301 Nasal Spray Being Developed for COVID-19
August 31, 2020
Atossa Therapeutics Announces Enrollment and Dosing Completed in First Group of Healthy Participants in Clinical Study of AT-301 Nasal Spray Being Developed for Treatment of COVID-19
August 16, 2020
Atossa Therapeutics Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 12, 2020
Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19
August 2, 2020
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
July 29, 2020
Atossa Therapeutics Contracts for Clinical Study of AT-301 Nasal Spray, Atossa’s Second COVID-19 Therapeutic Development Program
July 15, 2020
Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
July 14, 2020
Atossa Therapeutics Advances Product Development Programs with Multiple Key Hires in Clinical, Regulatory, and Chemistry Manufacturing and Controls
July 7, 2020
Atossa Therapeutics Announces Availability of Manuscript on Results from In vitro Testing of COVID-19 Drug, AT-H201
June 10, 2020
Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study
May 27, 2020
Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
May 19, 2020
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
May 12, 2020
Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
May 6, 2020
Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study
April 26, 2020
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
April 19, 2020
Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program
April 15, 2020
Atossa Therapeutics Announces Clinical Progress
April 1, 2020
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
March 25, 2020
Atossa Therapeutics Announces Upcoming Meeting with FDA
March 12, 2020
Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density
March 1, 2020